KALA BIO (KALA) Competitors $1.57 -0.07 (-4.27%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.59 +0.02 (+1.21%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. BCAB, JSPR, ELUT, SNTI, OKUR, RANI, MURA, EGRX, ATHE, and TENXShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include BioAtla (BCAB), Jasper Therapeutics (JSPR), Elutia (ELUT), Senti Biosciences (SNTI), OnKure Therapeutics (OKUR), Rani Therapeutics (RANI), Mural Oncology (MURA), Eagle Pharmaceuticals (EGRX), Alterity Therapeutics (ATHE), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors BioAtla Jasper Therapeutics Elutia Senti Biosciences OnKure Therapeutics Rani Therapeutics Mural Oncology Eagle Pharmaceuticals Alterity Therapeutics Tenax Therapeutics BioAtla (NASDAQ:BCAB) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Do institutionals & insiders believe in BCAB or KALA? 77.2% of BioAtla shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 11.2% of BioAtla shares are owned by company insiders. Comparatively, 8.3% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend BCAB or KALA? KALA BIO has a consensus target price of $20.38, indicating a potential upside of 1,197.77%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts clearly believe KALA BIO is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings & valuation, BCAB or KALA? KALA BIO has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M4.88-$69.78M-$1.10-0.83KALA BIO$3.89M2.83-$38.51M-$6.79-0.23 Does the media prefer BCAB or KALA? In the previous week, KALA BIO had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for KALA BIO and 2 mentions for BioAtla. BioAtla's average media sentiment score of 0.99 beat KALA BIO's score of -0.11 indicating that BioAtla is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCAB or KALA more profitable? KALA BIO's return on equity of -686.43% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% KALA BIO N/A -686.43%-76.81% Which has more volatility & risk, BCAB or KALA? BioAtla has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.1, suggesting that its share price is 310% less volatile than the S&P 500. SummaryKALA BIO beats BioAtla on 8 of the 15 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.52M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-0.2321.5785.6527.61Price / Sales2.83271.42538.60201.06Price / CashN/A47.1237.9261.55Price / Book0.7810.1412.966.76Net Income-$38.51M-$52.31M$3.30B$275.88M7 Day Performance1.95%5.14%4.32%2.81%1 Month Performance-88.79%14.68%9.47%9.24%1 Year Performance-69.40%30.98%84.27%35.42% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO4.1261 of 5 stars$1.57-4.3%$20.38+1,197.8%-70.4%$11.52M$3.89M-0.2330Analyst ForecastShort Interest ↑BCABBioAtla0.7288 of 5 stars$0.67-3.0%N/A-55.4%$39.17M$11M-0.6160JSPRJasper Therapeutics3.4508 of 5 stars$2.40+0.6%$25.63+969.9%-84.9%$38.92MN/A-0.4020Analyst ForecastELUTElutia3.0833 of 5 stars$0.89+0.1%$7.00+685.6%-76.7%$38.16M$23.68M-0.85180Analyst ForecastGap UpHigh Trading VolumeSNTISenti Biosciences1.9607 of 5 stars$1.43+1.4%$8.50+494.4%-25.2%$37.41M$2.56M-0.164Analyst ForecastOKUROnKure Therapeutics3.299 of 5 stars$2.68-2.5%$32.33+1,106.5%N/A$36.26MN/A-0.56N/AAnalyst ForecastRANIRani Therapeutics2.6971 of 5 stars$0.50+0.8%$7.33+1,355.0%-77.6%$36.22M$1.03M-0.55110Analyst ForecastMURAMural Oncology3.3824 of 5 stars$2.08+0.2%$12.00+478.3%-40.1%$35.95MN/A-0.24119Analyst ForecastEGRXEagle Pharmaceuticals1.4492 of 5 stars$2.70flatN/A+445.5%$35.07M$257.55M0.00100ATHEAlterity Therapeutics2.5236 of 5 stars$3.93+4.5%$12.00+205.3%+226.5%$34.86MN/A0.0010News CoveragePositive NewsAnalyst ForecastGap UpTENXTenax Therapeutics1.9896 of 5 stars$7.64+0.4%$18.00+135.6%+140.9%$34.84MN/A-8.309High Trading Volume Related Companies and Tools Related Companies BioAtla Competitors Jasper Therapeutics Competitors Elutia Competitors Senti Biosciences Competitors OnKure Therapeutics Competitors Rani Therapeutics Competitors Mural Oncology Competitors Eagle Pharmaceuticals Competitors Alterity Therapeutics Competitors Tenax Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
